Some aspects of the treatment of adult patients with Epstein-Barr virus infection


Cite item

Full Text

Abstract

The review analyzes the basic aspects of treatment policy in patients with different forms of Epstein-Barr virus infection. Practical recommendations are given on the basis of the extensive literature data published in the past 20 years.

Full Text

Некоторые аспекты лечения взрослых больных инфекцией, вызванной вирусом Эпштейна-Барр. - Аннотация. В обзоре проанализированы основные аспекты лечебной тактики ведения больных с различными формами инфекции, вызванной вирусом Эпштейна-Барр. На основании обширных данных литературы, опубликованных за последние 20 лет, приведены практические рекомендации.
×

References

  1. Epstein M.A. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702.
  2. Henle G., Henle W., Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968; 59 (1): 94-101.
  3. Sawyer R.N., Evans A.S., Niederman J.C., McCollum R.W. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. J Infect Dis 1971; 123 (3): 263-270.
  4. Cohen J.I. Epstein-Barr virus infection. New Engl J Med 2000; 343 (7): 481-491.
  5. Foerster J. Infectious mononucleosis. In: Lee. Wintrobe's Clinical Hematology. 10th ed. 1999: 1926-1955.
  6. Li Z.Y., Lou J.G., Chen J. Analysis of primary symptoms and disease spectrum in Epstein-Barr virus infected children. Zhonghua Er Ke Za Zhi 2004; 42 (1): 20-22.
  7. Grotto I., Mimouni D., Huerta M. et al. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults Epidemiol Infect 2003; 131 (1): 683-689.
  8. Поляков В.Е., Лялина В.Н., Воробьева М.Л. Инфекционный мононуклеоз (болезнь Филатова) у детей и подростков. Эпидемиол и инфекц бол 1998; 6: 50-54.
  9. Gershburg E., Pagano J.S. Epstein-Barr infections: prospects for treatment. J Antimicrob Chemother 2005; 56 (2): 277-281.
  10. Behrman R.E., Kliegman R.M., Jenson H.B. (ed). Nelson textbook of pediatrics, 17th еd. 2004: 2615-2619.
  11. Okano M. Epstein-Barr virus infecion and its role in the expanding spectrum of human diseases. Acta Paediatr 1998; 87 (1): 11-18.
  12. Pagano J.S. Viruses and lymphomas. N Engl J Med 2002; 347 (2): 78-79.
  13. Lande M.B. Immune complex disease associated with Epstein-Barr virus infectious mononucleosis. Pediatr Nephrol 1998; 12 (8): 651-653.
  14. Cohen J.I., Kimura H., Nakamura S. et al. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008 Ann Oncol 2009; 20 (9): 1472-1482.
  15. Faulkner G.C., Krajewski A.S., Crawford A. The ins and outs of EBV infеction. Trends Microbiol 2000; 8: 185-189.
  16. Chaganti S., Ma C.S., Bell A.I. et al. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. Blood 2008; 112 (3): 672-679.
  17. Crawford D.H., Macsween K.F., Higgins C.D. et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006; 43: 276-282.
  18. Gulley M.L., Glaser S.L., Craig F.E. et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol 2002; 117: 259-267.
  19. Hjalgrim H., Askling J., Rostgaard K. et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-1332.
  20. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 1994; 21 (3): 376-381.
  21. Hanto D.W. Classification of Epstein-Barr virus-associated post transplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381-394.
  22. Tosato G., Taga K., Angiolillo A.L., Sgadari C. Epstein-Barr virus as an agent of haematological disease. Baillieres Clin Haematol 1995; 8 (1): 165-199.
  23. Schooley R.T. Epstein-Barr virus (infectious mononucleosis). In: Mandell. Principles and Practice of Infectious Diseases. 5th ed. 2000: 1599-1608.
  24. Малашенкова И.К., Дидковский Н.А., Говорун В.М., Ильина Е.Н. Роль вируса Эпштейна-Барр в развитии синдрома хронической усталости и иммунной дисфункции. Int J Immunorehabilitat 2000; 1: 102-111.
  25. Никольский И.С., Юрченко В.Д., Никольская К.И. Характеристика активной хронической Эпштейна-Барр-вирусной инфекции: клинико-иммунологический синдром. Совр инфекц 2003; 3: 60-62.
  26. Anderson J. Clinical and immunological considerations in Epstein-Barr virus associated diseases. Scand J Infect Dis 1996; Suppl. 100: 72-82.
  27. Yamashita S., Murakami C., Izumi Y. Severe chronic active Epstein- Barr virus infection accompanied by virus-associated hemophagocytic syndrome, cerebellar ataxia and encephalitis. Psychiatry Clin Neurosci 1998; 52 (4): 449-452.
  28. Lekstron-Himes J.A., Dale J.K., Kingma D.W. Periodic illness associated with Epstein-Barr virus infection. Clin Infect Dis 1996; 22 (1): 22-27.
  29. Schooley R.T., Carey R.W., Miller G. et al. Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med 1986; 104 (5): 636-643.
  30. Maakaroun N.R., Moanna A., Jacob J.T., Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol 2010; 20 (2): 93-105.
  31. Manika K., Alexiou-Daniel S., Papakosta D. et al. Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24 (2): 134-140.
  32. Candy B., Chalder T., Cleare A.J. et al. Predictors of fatigue following the onset of infectious mononucleosis. Psychol Med 2003; 33 (5): 847-855.
  33. Katz B.Z., Shiraishi Y., Mears C.J. et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 2009; 124 (1): 189-193.
  34. Straus S.E. The chronic mononucleosis syndrome J Infect Dis 1988; 157 (3): 405-412.
  35. Tobi M., Straus S.E. Chronic mononucleosis a legitimate diagnosis Postgrad Med 1988; 83 (1): 69-78.
  36. Краснов В.В. Инфекционный мононуклеоз. Клиника, диагностика, современные принципы лечения. СПб: Н. Новгород 2003.
  37. Ebell M.H. Epstein-Barr Virus Infectious Mononucleosis Fam. Physician 2004; 70 (7): 1279-1287.
  38. Okano M., Gross G. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients. Expert Rev Anti Infect Ther 2007; 5 (3): 403-413.
  39. Dalrymple W. Infectious mononucleosis. Relation of bed rest and activity to prognosis. Postgrad Med 1964; 35: 345-349.
  40. Кудин А.П. Эта "безобидная" вирус Эпштейна-Барра инфекция. Часть 2. Острая ВЭБ-инфекция: эпидемиология, клиника, диагностика, лечение. Мед новости 2006; 8: 25-31.
  41. Vendelbo J.L., Lildholdt T., Bende M. et al. Infectious mononucleosis treated by an antihistamine: a comparison of the efficacy of ranitidine (Zantac) vs placebo in the treatment of infectious mononucleosis. Clin Otolaryngol 1997; 22: 123-125.
  42. Боковой Ф.Г., Лыкова Е.А., Дегтярева В.А. и др. Лечение острых форм инфекционного мононуклеоза у детей в стационаре. Эпидемиол и инфекц бол 2007; 1: 53-56.
  43. Fota-Markowcka H. Profile of microorganisms isolated in nasopharyngeal swabs from the patients with acute infectious mononucleosis. Wiad Lek 2002; 55 (3-4): 150-157.
  44. Tynell E., Aurelius E., Brandell A. et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis 1996; 174: 324-331.
  45. Roy M., Bailey B., Amre D.K. et al. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Archiv Pediatric Adolescent Med 2004; 158: 250-254.
  46. Epstein-Barr virus and infectious mononucleosis. Accessed online August 16, 2004, at: http://www.cdc.gov/ncidod/diseases/ebv.htm
  47. Казмирчук В.Е., Мальцев Д.В. Рекомендации по лечению герпесвирусных заболеваний человека. Врачу-практику 2012: 5 (91); IX/X.
  48. Furman P.A., de Miranda P., St. Clair M.H. et al. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother 1981; 20: 518-524.
  49. St Clair M.H., Furman P.A., Lubbers C.M. et al. Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother 1980; 18: 741-745.
  50. Meerbach A. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antivir Chem Chemother 1998; 9 (3): 275-282.
  51. Torre D., Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 1999; 31: 543-547.
  52. Van der Horst C., Joncas J., Ahronheim G. et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis 1991; 164: 788-792.
  53. Wu Y., Luo C., Lu Z. et al. Curative effect of interfon-alpha in children with infectious mononucleosis. Hua Xi Yi Ke Da Xue Xue Bao 1996; 27 (1): 82-84.
  54. Sakai Y., Ohga S., Tonegawa Y. et al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol 1998; 20 (4): 342-346.
  55. O'Brien S., Bernert R.A., Logan J.L., Lien Y.H. Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 1997; 8 (9): 1483-1489.
  56. Winston D.J., Eron L.J., Ho M. et al. Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med 1988; 85 (2): 147-151.
  57. Toraldo R., D'Avanzo M., Tolone C. et al. Effect of interferon-alpha therapy in a patient with common variable immunodeficiency and chronic Epstein-Barr virus infection. Pediatr Hematol Oncol 1995; 12 (5): 489-493.
  58. Okano M., Pirruccello S.J., Grierson H.L. et al. Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-alpha. Clin Immunol Immunopathol 1990; 54 (3): 410-408.
  59. Ferrara G., Zumla A., Maeurer M. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. Am J Med 2012; 125 (10): 1036.e1-1036.e8.
  60. Ma C., Wong C.K., Wong B.C. et al. Cytokine responses in a severe case of glandular fever treated successfully with foscarnet combined with prednisolone and intravenous immunoglobulin. J Med Virol 2009; 81 (1): 99-105.
  61. Казмірчук В.Є., Мірошникова М.І. Лікування ускладнених форм Епштейна-Барр вірусної інфекції. Сучасні інфекції 2002; 4: 8-12.
  62. Филатов Л.Б., Пивник А.В. Ритуксимаб в лечении аутоиммунных цитопений. Совр онкол 2008; 2: 1-20.
  63. Gong Q., Ou Q., Ye Sh. et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826.
  64. Fernαndez-Ruiz M., San-Juan R., Aguado J.M. Epstein-Barr virus DNAemia and infectious complications after preemptive rituximab treatment. Transplantation 2013; 95 (3): e13.
  65. Petropoulou A.D., Porcher R., Peffault de Latour R. et al. Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation. Transplantation 2012; 94 (8): 879-883.
  66. Cohen J.I., Jaffe E.S., Dale J.K. et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood 2011; 117 (22): 5835-5849.
  67. Демиденко Т.Д., Ермакова Н.Г. Основы реабилитации неврологических больных. СПб: ФОЛИАНТ 2004; 304.
  68. Мохорт Т.В. Возможности коррекции и профилактики синдрома хронической усталости. Мед новости 2003; 2: 71-78.
  69. Albrecht F. Chronic fatigue syndrome. J Am Acad Child Adolesc Psychiatry 2000; 39 (7): 808-809.
  70. Rea T.D., Russo J.E., Katon W. et al. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract 2001; 14: 234-242.
  71. Candy B., Chalder T., Cleare A.J. et al. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract 2002; 52: 844-851.
  72. Epstein M.A., Morgan A.J., Finerty S. et al. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985; 318: 287-289.
  73. Gu S.-Y., Huang T.-M., Ruan L. et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84: 171-177.
  74. Jackman W.T., Mann K.A., Hoffmann H.J., Spaete R.R. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for EBV subunit vaccine. Vaccine 1999; 17: 660-668.
  75. Khanna R., Moss D.J., Burrows S.R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999; 170: 49-64.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies